Baijin Life Science Holdings Limited (Stock Code: 1466) reported revenue of HK$55.1 million for the six months ended 30 September 2025, compared to HK$70.9 million for the same period in 2024. The gross profit was HK$8.5 million, down from HK$16.8 million in the prior year. Profit attributable to owners of the Company reached HK$2.2 million, turning around from a loss of HK$6.2 million a year earlier. Overall profit for the period was HK$2.5 million, reversing from a HK$1.9 million loss last year.

According to the announcement, the jewellery business recorded revenue of HK$43.5 million, while the skincare business contributed HK$11.6 million. The reduced overall revenue, alongside cost adjustments, resulted in a lower gross profit margin of 15.4%. Management highlighted a gain from the change in fair value of a convertible bond as a key factor supporting the turnaround in results.

As at 30 September 2025, total equity stood at HK$157.8 million, compared to HK$155.9 million at 31 March 2025. Cash and cash equivalents amounted to HK$57.5 million, up from HK$47.8 million at the end of March 2025. Major capital activities in the period included share subscriptions completed earlier, with net proceeds deployed for general working capital. The announcement indicated no interim dividend recommendation.

The announcement also mentioned the successful receipt of a compensation amount of HK$41.97 million relating to a performance guarantee linked to a previously acquired subsidiary. Furthermore, a convertible bond with a principal amount of HK$31.5 million was converted in early October 2025, resulting in the issue of additional shares. Management noted that the Group will continue developing its jewellery business, expanding skincare operations (including a new flagship beauty club), and monitoring strategic investments to strengthen overall business performance.